



Continually Communicate: MMRF Strategy Meeting with Board of Directors

KPMA Tools: MMRF Case Study

AGENDA

9:00am – 10:00am

10:00am – 10:05am

10:05am – 10:10am

10:10am – 11:20am

11:20am – 11:40am

11:40am – 12:00pm

12:00pm – 12:30pm

12:30pm – 1:55pm

1:55pm – 2:00pm

2:00pm – 3:00pm

3:00pm

Breakfast

Call to Order

Welcome & Introduction

Committee Reports ~ Committee Chairs

- *Human Resources*
- *Resource Development*
- *Programming*
- *Audit & Finance*
- *Board Development*
- *Myeloma Investment Fund*

Strategic Landscape

Strategic Plan Overview

Lunch

Strategic Discussion

- *Marketing*
- *Philanthropy*
- *Biopharma*

Corporate Governance & Approvals


Executive Session

Adjourn

STRATEGIC PLAN OVERVIEW

MMRF MODEL

We built the first and only end-to-end model in cancer research, driving toward a cure for every patient.



MMRF (2019-2021) STRATEGIC PLAN

The MMRF plan represents 50 interviews resulting in three strategic pillars.

ADVISORS



KEY CHALLENGES

Immune research is inefficient and fragmented

Competition causing hesitancy to invest

Lack of community access to best data and insights

STRATEGIC IMPERATIVES

- 1 Accelerate immune as precision patient care model
- 2 Entice research by harnessing venture
- 3 Aggregate data to identify new targets & care pathways

IMMUNE CHALLENGE

While immune efforts are vast, they are fragmented and inefficient.

Potential and Reality of IO

>2,000

IO agents in development,
~half in clinical stages

>600

Biopharma and AMCs
with IO pipelines

>500,000

Multiple disparate
approaches require high
volume of patients

Need for rational approach:

Myeloma focus

Best targets

Right patients

Greater access

THREE PILLARS OF IMMUNE PLAN

Strategies

Components

	Immune Atlas	Clinical Acceleration	Prevention
Strategies	Establish a standardized immune profiling platform	Accelerate new discovery and clinical insights through novel studies	Develop and apply patient profiling insights for early stage patients
Components	<ul style="list-style-type: none"> • Assay selection and standardization • Data analysis of existing MMRF assets • New, complementary sample protocol strategy 	<ul style="list-style-type: none"> • Pre-clinical funding program • MMRF IST Incubator • New platform trials 	<ul style="list-style-type: none"> • Registry partnership with PROMISE / PCROWD studies • Sample study of SMM patients • Clinical studies

VENTURE CHALLENGE

Traditional venture models perpetuate siloed research and lack of myeloma focus.

Reality of Pipeline	
~1,100	IO assets in preclinical development
~40	IO preclinical assets being studied in myeloma (out of 1,100)
26	IO assets FDA approved
2	IO assets approved in myeloma (out of 26)

Need for rational approach:


Focus in myeloma

Portfolio of distributed risk

Rational investment decisions

VENTURE FUND ADVANTAGE

The Myeloma Investment Fund will operate as a boutique research firm.



COMMUNITY DEMOCRATIZATION OF CARE

The majority of patients are treated in community centers with worse outcomes.

Reality of Community Care

Top 10

60%

Worse

AMCs treat only 10% of myeloma patients

Myeloma patients treated in community centers

Outcomes for patients at lower volume centers

Need for rational approach:

Sub-type data access


Decision-support

Precision care pathways

KOL endorsement

NEED FOR DATA INTEGRATION TO DRIVE VALUE

Data aggregation and integration is necessary to answer the most critical questions.



Generating sufficient data → Framing the right questions → Delivering value to patients

CURECLOUD – PATIENT REGISTRY

First-of-its-kind DTP initiative – expected launch in Q2 2019.



How do I become part of the cure?



Pilot completed
with 35 patients

EMR extraction
successful


Gene panel and sign-
out / reporting in
validation for CLIA

Counseling services
in process


DEMOCRATIZED CARE – PILOT OVERVIEW

Develop, implement, and validate use of treatment decision support tool within IMH’s provider network to improve patient outcomes.


AGGREGATE DATA



DEVELOP DECISION SUPPORT TOOL



VALIDATE AND IMPLEMENT



OUR COMMITMENT

SMARTER
FASTER
CURE

WORK
SMARTER

Create breakthroughs in
immuno-oncology and genomics

WORK
FASTER

Accelerate investment and scale
through a venture fund

WORK TOWARD A
CURE

Democratize access to data for
every patient

STRATEGY → OPERATIONS

Operationalizing our strategic plan requires prioritization, resourcing, and process.

1

Ensure **prioritization** based on impact, time, and cost

2

Support with appropriate **resources** and funding models

3

Drive momentum and accountability through **process**